{"url_path":"/sec/cik-0001460602/8-k/2026-06-02/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1460602/0001493152-26-026914-index.html","accession_number":"0001493152-26-026914","cik":"0001460602","ticker":null,"issuer_name":"Orgenesis Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1460602/0001493152-26-026914-index.html","primary_entity_key":"0001460602","primary_entity_name":"Orgenesis Inc."},"word_count":280,"has_tables":true,"body_markdown":"**Item\n5.07 Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn\nMay 27, 2026, the Company held the Special Meeting via live webcast. At the Special Meeting, 6,415,731 shares of common stock, or approximately\n65.27% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person, representing a quorum.\n\n \n\nAt\nthe Special Meeting, the stockholders of the Company voted as set forth below on three proposals, each of which is described in detail\nin the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 5, 2026 and as amended on\nMay 20, 2026. The final voting results for each matter submitted to a vote of the Company’s stockholders are as follows:\n\n \n\n**Proposal\n1. Amendment to Articles of Incorporation to Increase Authorized Shares of Common Stock**\n\n \n\nThe\napproval of a proposal to approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the number of\nauthorized shares of common stock from 14,583,333 to 150,000,000:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n\n5,153,345\n \n61,005\n \n1,201,381\n\n** **\n\n**Proposal\n2. Share Issuance Proposal**\n\n \n\nThe\napproval of the Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, Orgenesis Inc., and Alpha\nProsperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P, and the potential issuance of shares of common\nstock of Orgenesis Inc. pursuant thereto:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n\n5,172,526\n \n27,026\n \n1,201,280\n\n \n\n**Proposal\n3. Ratification of Auditors**\n\n \n\nThe\napproval of the ratification of the appointment of Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International\nLimited, as our independent registered public accounting firm for the fiscal year ending December 31, 2025:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n\n6,400,038\n \n14,552\n \n1,141"}